新闻ALTEOGEN Inc. partnered with Tesaro Inc on Jan 1st '26.In January 2026, Alteogen entered an exclusive licence agreement with Tesaro, a GSK subsidiary, for the use of ALT-B4 in the development and commercialisation of a subcutaneous formulation of dostarlimab.
新闻AnaptysBio, Inc. filed suit against Tesaro Inc on Jul 1st '14.AnaptysBio promptly filed a countersuit claiming that Tesaro, under pressure from GSK, had unlawfully modified the terms of the 2014 agreement.
新闻Tesaro Inc is developing Jemperli on Apr 24th '26.Currently, under the Collaboration Agreement, Tesaro is developing Jemperli (dostarlimab) as a monotherapy, and in combination with additional therapies, for various solid tumor indications.
